US Patent

US8129343 — Acylated GLP-1 compounds

Method of Use · Assigned to Novo Nordisk AS · Expires 2031-12-05 · 6y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of acylated GLP-1 compounds for therapeutic purposes.

USPTO Abstract

Protracted GLP-1 compounds and therapeutic uses thereof.

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2202`	—	Ozempic
`U-2628`	—	Ozempic
`U-2628`	—	Ozempic
`U-3469`	—	Ozempic
`U-2628`	—	Ozempic
`U-2628`	—	Ozempic
`U-2202`	—	Ozempic
`U-2628`	—	Ozempic
`U-2628`	—	Ozempic
`U-3355`	—	Ozempic

Patent Metadata

Patent number: US8129343
Jurisdiction: US
Classification: Method of Use
Expires: 2031-12-05
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.